Ionis Pharmaceuticals (IONS) EBIAT (2016 - 2025)
Historic EBIAT for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to -$128.6 million.
- Ionis Pharmaceuticals' EBIAT rose 845.24% to -$128.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$256.3 million, marking a year-over-year increase of 2855.79%. This contributed to the annual value of -$453.9 million for FY2024, which is 2391.87% down from last year.
- According to the latest figures from Q3 2025, Ionis Pharmaceuticals' EBIAT is -$128.6 million, which was up 845.24% from $123.6 million recorded in Q2 2025.
- In the past 5 years, Ionis Pharmaceuticals' EBIAT registered a high of $224.6 million during Q4 2021, and its lowest value of -$147.4 million during Q3 2023.
- Moreover, its 5-year median value for EBIAT was -$85.3 million (2023), whereas its average is -$66.9 million.
- As far as peak fluctuations go, Ionis Pharmaceuticals' EBIAT tumbled by 102651.41% in 2024, and later skyrocketed by 28644.99% in 2025.
- Over the past 5 years, Ionis Pharmaceuticals' EBIAT (Quarter) stood at $224.6 million in 2021, then tumbled by 123.34% to -$52.4 million in 2022, then surged by 82.33% to -$9.3 million in 2023, then plummeted by 1026.51% to -$104.3 million in 2024, then fell by 23.25% to -$128.6 million in 2025.
- Its EBIAT was -$128.6 million in Q3 2025, compared to $123.6 million in Q2 2025 and -$146.9 million in Q1 2025.